Seizing the strategic opportunities of emerging technologies by building up innovation system: monoclonal antibody development in China

被引:0
作者
Mao-Yu Zhang
Jian Li
Hao Hu
Yi-Tao Wang
机构
[1] University of Macau,State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences
[2] University of Macau,Faculty of Arts and Humanity
来源
Health Research Policy and Systems | / 13卷
关键词
China; Emerging technology; Innovation system; Monoclonal antibody;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 114 条
[1]  
Buss N(2012)Monoclonal antibody therapeutics: history and future Curr Opin Pharmacol. 12 615-22
[2]  
Henderson S(2011)Advances in the production and downstream processing of antibodies N Biotechnol. 28 458-63
[3]  
Chon JH(1975)Continuous cultures of fused cells secreting antibody of predefined Nature. 256 495-7
[4]  
Zarbis-Papastoitsis G(2001)Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies Int Immunol. 13 1551-9
[5]  
Köhler G(2005)Immunogenicity of engineered antibodies Methods. 36 3-10
[6]  
Milstein C(1984)Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains Proc Natl Acad Sci U S A. 81 6851-5
[7]  
Ober RJ(2008)Monoclonal antibodies as innovative therapeutics Curr Pharm Biotechnol. 9 423-30
[8]  
Radu CG(2010)Development trends for human monoclonal antibody therapeutics Nat Rev Drug Discov. 9 767-74
[9]  
Ghetie V(2013)Entry strategies in an emerging technology: a pilot web-based study of graphene firms Scientometrics. 95 1189-207
[10]  
Ward ES(2013)Management innovation and adoption of emerging technologies: the case of cloud computing Eur Manag Rev. 10 51-67